EU approves Regeneron-Sanofi Dupixent for chronic urticaria in children 2-11
Share
Listen to the news
EU approves Regeneron-Sanofi Dupixent for chronic urticaria in children 2-11
  • European Commission cleared Dupixent (dupilumab) for moderate-to-severe chronic spontaneous urticaria in children aged 2-11 years who remain symptomatic on H1 antihistamines.
  • Label applies to patients who are naïve to anti-IgE therapy for CSU.
  • Decision expands Dupixent EU CSU indication beyond adults and adolescents aged 12 years and older.
  • Regeneron noted US regulators accepted a supplemental biologics application for Dupixent in certain children aged 2-11 years with CSU.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604130100PRIMZONEFULLFEED9688028) on April 13, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending